This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Doctor Reddy's (RDY) have performed compared to their sector so far this year.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CLRG
McKesson (MCK) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $375.12, marking no change from the previous day.
Are Investors Undervaluing McKesson (MCK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
McKesson (MCK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $383.67, marking a +0.49% move from the previous day.
McKesson (MCK) Announces Availability of FDA-Accepted Drug
by Zacks Equity Research
The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PEComa.
McKesson (MCK) Announces Availability of FDA-Approved Drug
by Zacks Equity Research
The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for AML.
Should JPMorgan Diversified Return U.S. Equity ETF (JPUS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPUS
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $375.54, marking a +0.78% move from the previous day.
All You Need to Know About McKesson (MCK) Rating Upgrade to Buy
by Zacks Equity Research
McKesson (MCK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HCA Healthcare's (HCA) ESR Program Aids Post-Surgery Recovery
by Zacks Equity Research
HCA Healthcare's (HCA) ESR program remains on track to attract more patients to choose HCA's healthcare facilities for undergoing surgeries.
Are Medical Stocks Lagging Immunovant (IMVT) This Year?
by Zacks Equity Research
Here is how Immunovant, Inc. (IMVT) and McKesson (MCK) have performed compared to their sector so far this year.
McKesson (MCK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $377.75, moving +1.71% from the previous trading session.
LabCorp (LH) Gains on Innovation Amid Currency Headwinds
by Zacks Equity Research
LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to help match patients with critical and potentially life-changing treatments for cancer and other diseases.
3 Non-Energy S&P 500 Stocks With Enough Energy to Boost Returns
by Kinjel Shah
Though energy companies have been among the best-performing stocks in the S&P 500 index, here we discuss some top-performing non-energy S&P 500 stocks like MRK, VRTX and MCK.
Cooper Companies (COO) Q4 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal fourth-quarter revenues reflect a solid segmental performance.
LabCorp's (LH) New APH Lab to Expand Global Capabilities
by Zacks Equity Research
LabCorp's (LH) new laboratory is likely to advance clinical trials across therapeutic areas like oncology, hemato-oncology and liver diseases.
Masimo (MASI) W1 Watch With Hi to Improve Patient Outcome
by Zacks Equity Research
Masimo's (MASI) full-market release of the Hi for the Masimo W1 watch is likely to significantly improve RPM.
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
Zimmer Biomet (ZBH) Procedure Volume Gain Aids Amid FX Hurdles
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to face significant challenges in terms of unfavorable foreign exchange, supply, inflation and staffing shortage.
3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.